Calvo J R, Guerrero J M, López-Gonzalez M A, Osuna C, Segura J J
Department of Medical Biochemistry and Molecular Biology, School of Medicine, University of Sevilla, Spain.
Peptides. 1994;15(2):309-15. doi: 10.1016/0196-9781(94)90018-3.
Vasoactive intestinal peptide (VIP) receptors were investigated in rat peritoneal macrophage membranes (RPMM) using [125I]VIP as ligand. The receptor binding was rapid, reversible, saturable, specific, and dependent on time, temperature, and membrane concentration. The Scatchard analysis of binding data was consistent with the existence of two classes of VIP binding sites with Kd values of 0.60 +/- 0.08 and 275 +/- 39 nM and binding capacities of 580 +/- 71 and 72,500 +/- 810 fmol VIP/mg protein, respectively. The interaction showed a high degree of specificity, as suggested by competitive displacement experiments with several peptides structurally or not structurally related to VIP. These pharmacological studies showed the following order of potency: VIP (IC50 = 1 nM) > rGRF (IC50 = 13 nM) > PHI (IC50 = 421 nM) >> secretin. Glucagon, somatostatin, insulin octapeptide of cholecystokinin [CCK(26-33)], and pancreastatin were ineffective at concentrations up to 1 microM. Binding of [125I]VIP to membranes is markedly reduced by increasing the ionic strength of incubation medium. Treatment of membranes with dithiothreitol, trypsin, and phospholipases A2 and C resulted in a loss of the ability of these membranes to bind VIP. However, treatment with phospholipase D did not affect binding of VIP by membranes. The molecular characterization of VIP receptors in RPMM was performed after [125I]VIP cross-linking to membranes using the cross-linker dithiobis (succinimidyl propionate). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of membrane proteins revealed specific [125I]VIP-protein complexes of M(r) 55,000 +/- 1700, 35,000 +/- 900, and 22,000 +/- 500.
利用[125I]血管活性肠肽(VIP)作为配体,对大鼠腹膜巨噬细胞膜(RPMM)中的VIP受体进行了研究。受体结合迅速、可逆、可饱和、具有特异性,且依赖于时间、温度和膜浓度。结合数据的Scatchard分析表明存在两类VIP结合位点,其解离常数(Kd)值分别为0.60±0.08和275±39 nM,结合容量分别为580±71和72,500±810 fmol VIP/mg蛋白质。如与几种与VIP在结构上或非结构上相关的肽进行的竞争置换实验所示,这种相互作用表现出高度的特异性。这些药理学研究显示出以下效力顺序:VIP(半数抑制浓度[IC50]=1 nM)>大鼠生长激素释放因子(rGRF,IC50 = 13 nM)>肽组氨酸异亮氨酸(PHI,IC50 = 421 nM)>>促胰液素。胰高血糖素、生长抑素、胆囊收缩素八肽[CCK(26 - 33)]和胰抑制素在浓度高达1 microM时均无作用。通过增加孵育介质的离子强度,[125I]VIP与膜的结合显著减少。用二硫苏糖醇、胰蛋白酶、磷脂酶A2和C处理膜会导致这些膜结合VIP的能力丧失。然而,用磷脂酶D处理并不影响膜对VIP的结合。在使用交联剂二硫代双(琥珀酰亚胺丙酸酯)将[125I]VIP与膜交联后,对RPMM中的VIP受体进行了分子表征。膜蛋白的十二烷基硫酸钠-聚丙烯酰胺凝胶电泳显示出分子量(M(r))为55,000±1700、35,000±900和22,000±500的特异性[125I]VIP-蛋白质复合物。